ALLR
Income statement / Annual
Last year (2024), Allarity Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Allarity Therapeutics, Inc.'s net income was -$24.52 M.
See Allarity Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$120.00 K |
$1.46 M |
$1.46 M |
$143.28 K |
$362.29 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.08 M
|
$2.22 M
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$120.00 K
|
-$3.62 M
|
-$761.50 K
|
$143.28 K
|
$362.29 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
1
|
-2.48
|
-0.52
|
1
|
1
|
| Research and Development Expenses |
$6.10 M
|
$7.10 M
|
$6.93 M
|
$14.20 M
|
$4.22 M
|
$6.37 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$11.44 M
|
$10.03 M
|
$9.96 M
|
$12.36 M
|
$4.10 M
|
$3.87 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.44 M
|
$10.03 M
|
$9.96 M
|
$12.36 M
|
$4.10 M
|
$3.87 M
|
$1.28 M
|
$3.07 M
|
$272.39 K
|
$89.15 K
|
| Other Expenses |
$9.70 M
|
$0.00
|
$17.57 M
|
$0.00
|
$0.00
|
$7.49 M
|
$84.39 K
|
$8.70 K
|
$4.36 M
|
$1.67 M
|
| Operating Expenses |
$27.24 M
|
$17.13 M
|
$34.46 M
|
$26.56 M
|
$8.32 M
|
$17.73 M
|
$1.36 M
|
$3.08 M
|
$4.63 M
|
$1.76 M
|
| Cost And Expenses |
$27.24 M
|
$17.13 M
|
$34.46 M
|
$26.56 M
|
$8.32 M
|
$17.73 M
|
$6.44 M
|
$5.30 M
|
$4.63 M
|
$1.76 M
|
| Interest Income |
$533.00 K
|
$22.00 K
|
$30.00 K
|
$0.00
|
$0.00
|
$7.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$653.00 K
|
$498.00 K
|
$223.00 K
|
$640.00 K
|
$320.00 K
|
$3.31 M
|
$233.24 K
|
$2.42 K
|
$43.70 K
|
$39.40 K
|
| Depreciation & Amortization |
$9.00 K
|
$37.00 K
|
$60.00 K
|
$106.00 K
|
$86.00 K
|
$51.00 K
|
$32.53 K
|
$8.70 K
|
$278.21 K
|
$265.22 K
|
| EBITDA |
-$24.23 M |
-$11.28 M |
-$17.30 M |
-$25.77 M |
-$6.01 M |
-$15.61 M |
-$4.90 M |
-$3.83 M |
-$4.21 M |
-$1.13 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
-130.12
|
-3.35
|
-2.63
|
-29.38
|
-3.12
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
-146.76
|
-3.41
|
-2.63
|
-31.32
|
-3.85
|
| Total Other Income/Expenses Net |
$2.35 M
|
$5.31 M
|
$16.88 M
|
$41.00 K
|
$1.90 M
|
-$1.37 M
|
$1.53 M
|
-$1.15 M
|
$37.99 K
|
-$130.58 K
|
| Income Before Tax |
-$24.90 M
|
-$11.82 M
|
-$17.58 M
|
-$26.52 M
|
-$6.42 M
|
-$18.98 M
|
-$3.46 M
|
-$4.99 M
|
-$4.45 M
|
-$1.53 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
-158.14
|
-2.37
|
-3.42
|
-31.06
|
-4.22
|
| Income Tax Expense |
-$381.00 K
|
$83.00 K
|
-$1.52 M
|
$133.00 K
|
$198.00 K
|
-$4.58 M
|
-$1.07 M
|
-$95.09 K
|
-$766.89 K
|
-$380.16 K
|
| Net Income |
-$24.52 M
|
-$11.90 M
|
-$16.06 M
|
-$26.65 M
|
-$6.60 M
|
-$14.31 M
|
-$2.29 M
|
-$4.90 M
|
-$3.68 M
|
-$1.15 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
-119.28
|
-1.57
|
-3.36
|
-25.7
|
-3.17
|
| EPS |
-15.791 |
-6153.264 |
-1856055 |
-3520104 |
-1698639 |
-189613 |
0 |
0 |
0 |
0 |
| EPS Diluted |
-15.791 |
-6153.264 |
-1856055 |
-3520104 |
-1698639 |
-189613 |
0 |
0 |
0 |
0 |
| Weighted Average Shares Out |
$1.61 M
|
$3.32 K
|
$11.34
|
$7.57
|
$3.89
|
$75.48
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Weighted Average Shares Out Diluted |
$1.61 M
|
$3.32 K
|
$11.34
|
$7.57
|
$3.89
|
$75.48
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
